Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
National Research Council Biotechnology Research Institute
NRC-BRI's Health and Bioprocess Sectors promote and conduct innovative collaborations, services and technology transfers with the biotechnology and pharmaceutical industries.
The company in detail
Profile
The Biotechnology Research Institute of the National
Research Council Canada (NRC-BRI) is the largest research
facility devoted to biotechnology in Canada. Through its
Health, Bioprocess and Environment sectors, the Institute
promotes, assists and conducts leading-edge R&D
collaborations, services and technology transfers with the
biotechnology and pharmaceutical industries.
The expertise of NRC-BRI's multidisciplinary research teams
in life sciences, forms a continuum that includes drug
discovery, bioprocess development and scale-
up. Committed to the practical applications of new
knowledge, NRC-BRI's scientific excellence, extensive
infrastructure, and outstanding track record in drug
discovery and development help reduce the technological
risks that its partners encounter.
NRC-BRI's Health Sector is highly involved in developing
cancer and infectious disease diagnostics and therapies.
The Health Sector research focuses on the identification of
molecular disease targets through the discovery and design
of lead drug
compounds.
NRC-BRI's Bioprocess Sector is specialized in the production
and purification of recombinant proteins from prokaryotic or
eukaryotic expression systems. The Sector scientists and
engineers utilize their world-class R&D expertise and
facilities
to assist pharmaceutical and biotechnology companies in the
development, optimization, scale-up of bioprocesses and the
production of bioproducts.
Partnering strategy/interests
NRC-BRI offers a range of opportunities for collaborations,
partnerships, fee for service, technology licensing and
laboratory space rental. NRC-BRI's partners include national
and international biotechnology and pharmaceutical
companies, universities and other governmental institutions.
R&D:
- Cancer and Infectious Diseases
- Genomics and Proteomics
- Molecular & Structural Biology
- Biopharmaceutical Development
- Bioprocesses Scale-up
- Eco-efficient Industrial Production
- Sustainable Industrial Process
- Environmental Protection
- Biochemical Engineering
- Biomass Conversion
- Bioremediation
- Pathogens Detection
SERVICES:
- Laboratory Space Rental (IPF)
- HTS Facility
- Microarray Facility
- Custom Antibodies Facility
- Custom Peptides Facility
- Flow Cytometry Facility
- Microscopy/Imaging Facility
- Biopharmaceutical Pilot Plant
- Biotreatability Facility
- Environmental Pilot Plant
- Biacore Facility
Out-licensing
High yield and low cost protein production in a few days to a couple of weeks (mg or g of protein). Production of proteins, including antibodies, for High-throughput screening assays, antibody generation and structure-activity analyses. More
Direct thrombin inhibitors designed for improved safety/efficacy profile. Peptide inhibitors suitable for cost-effective recombinant production.Anti-thrombin peptides that can be fused to homing peptides for targeted delivery or fused to markers. More
This method provides an efficient tool for rapid and precise identification of the molecular formula of small molecules, with some characterization of sub-structures, without a cumbersome process of compound isolation. More
Retractable inhibitors controlled through polypeptide-protein interactions with the flexible peptide bridge that link the two binding fragments may represent an alternative approach to antidote-reversible anticoagulant therapy. More
This technology provides a vector and a cell line that enables easy production of replicant. More
Modified versions of these tetracyclines were developed for applications directed toward the specific inhibition of calpains More
This rapid and precise on/off switch regulate the expression of transgenes in mammalian cells More
Novel carrier proteins for the production of small or large peptides as recombinant fusion proteins. More
The present invention provides a potent inhibitor of protein glycation and AGEs formation that is particularly advantageous for eye-drop delivery in the prevention and treatment of diabetes- and age-related pathologies. More
Assay for the identification of therapeutic agents that disrupt protein-protein interaction, L-11131
Mammalian cell-based reverse two-hybrid system to screen and identify drugs having the ability to disrupt the interaction between two candidate proteins. More
The cumate-inducible expression system allows turning on the expression of a given protein only when needed. More
This technology presents key improvements in expression vectors, serum-free media and process of a system for transient gene expression in human cells that have significantly increased the ease and yield of r-protein production. More
Delivering high performance at low cost, this sterilizable probe allows monitoring real-time fermentation processes. More
Enzymatic production of a broad range of biosurfactants including generation of molecules that cannot be prepared using chemical synthesis. More
The technology overcomes some limitations of conventional YTHS by extending its ability to detect interactions of biological relevance to the cytoplasm and the plasma membrane. More
Deals
To view this information, you must subscribe to Partneringtools.
Head office
National Research Council Biotechnology Research Institute
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Quebec
Tel: +1 514 496 6100
Fax: +1 514 496 5007
www | email
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Quebec
Tel: +1 514 496 6100
Fax: +1 514 496 5007
www | email
Contact details
Mr. Yves Quenneville
Business Development Officer
Industrial Affairs
Business Development Officer
Industrial Affairs
Company figures
Formed: 1987
Number of employees: 500
Number of employees: 500
Related categories
- Industry sector
- Biotechnology / Assay systems
- Biotechnology / Gene therapy
- Biotechnology / Human therapeutics
- Biotechnology / Human diagnostics
- Drug discovery
- Drug discovery / High throughput screening
- Drug discovery / Proteomics
- Drug discovery / Drug research platforms
- Government
- Technology transfer
- Research tools / Antibodies
- Research tools / Cell lines
- Research tools / Vectors
- Research tools / Biomarkers
- Research
- Therapeutic target
- Cardiovascular
- Cardiovascular / Thrombotic disorders / Thrombosis
- Infectious diseases
- Infectious diseases / Diseases / Infection, fungal (other)
- Oncology
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us